FIELD: chemical- -pharmaceutical industry. SUBSTANCE: lyophilized pharmaceutically acceptable composition formed by amorphous phase and crystalline phase includes at least one nonprotein active component and it has mannitol and alanine in the ratio R from 0.1 to 1 where R means the mass ratio of mannitol to alanine. Invention provides synergetic effect as result of coexisting the amorphous phase with crystalline phase. EFFECT: increased stability of composition. 12 cl, 11 tbl, 9 ex
Authors
Dates
2001-03-10—Published
1996-10-30—Filed